Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (9): 961-964.doi: 10.3969/j.issn.1000-6621.2021.09.017
• Original Articles • Previous Articles Next Articles
MA Ting-ting, REN Fei, MA Jin-bao(), YANG Han
Received:
2021-04-13
Online:
2021-09-10
Published:
2021-09-07
Contact:
MA Jin-bao
E-mail:772728767@qq.com
MA Ting-ting, REN Fei, MA Jin-bao, YANG Han. Resistance of prothionamided and sodium aminosalicylate among isoniazid resistant pulmonary tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 961-964. doi: 10.3969/j.issn.1000-6621.2021.09.017
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.09.017
患者特征 | 例数 | 丙硫异烟胺 | χ2值 | P值 | 对氨基水杨酸 | χ2值 | P值 | ||
---|---|---|---|---|---|---|---|---|---|
耐药(33例) | 敏感(816例) | 耐药(101)例) | 敏感(748例) | ||||||
耐多药 | 8.418 | 0.004 | 4.462 | 0.035 | |||||
是 | 515 | 28(5.44) | 487(94.56) | 71(13.79) | 444(86.21) | ||||
否 | 334 | 5(1.50) | 329(98.50) | 30(8.98) | 304(91.02) | ||||
治疗分类 | 6.413 | 0.011 | 0.936 | 0.333 | |||||
初治 | 582 | 16(2.75) | 566(97.25) | 65(11.17) | 517(88.83) | ||||
复治 | 267 | 17(6.37) | 250(93.63) | 36(13.48) | 231(86.52) |
[1] |
孔雨薇, 王立贵, 杜昕颖, 等. 2012—2018年北京市抗结核药物使用趋势分析. 中华医院感染学杂志, 2020, 30(8):1228-1233. doi: 10.11816/cn.ni.2020-193263.
doi: 10.11816/cn.ni.2020-193263 |
[2] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10):1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001 |
[3] |
Li G, Zhang J, Jiang Y, et al. Cross-resistance of isoniazid, para-aminosalicylic acid and pasiniazid against isoniazid-resistant Mycobacterium tuberculosis isolated in China. J Glob Antimicrob Resist, 2020, 20:275-281. doi: 10.1016/j.jgar.2019.08.005.
doi: 10.1016/j.jgar.2019.08.005 URL |
[4] |
刘银萍, 王杰, 张俊仙, 等. 对异烟肼与丙硫异烟胺耐药的结核分枝杆菌临床分离株检测及相关基因基因突变的研究. 中国防痨杂志, 2016, 38(9):718-721. doi: 10.3969/j.issn.1000-6621.2016.09.05.
doi: 10.3969/j.issn.1000-6621.2016.09.05 |
[5] |
周爱萍, 张敏, 李文侠, 等. 西安市耐异烟肼的结核杆菌耐药性及分子特征分析. 中国现代医学杂志, 2018, 28(12):53-57. doi: 10.3969/j.issn.1005-8982.2018.12.009.
doi: 10.3969/j.issn.1005-8982.2018.12.009 |
[6] |
Huo F, Lu J, Zong Z, et al. Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. BMC Infect Dis, 2019, 19(1):689. doi: 10.1186/s12879-019-4333-4.
doi: 10.1186/s12879-019-4333-4 URL |
[7] |
Vilchèze C, Jacobs WR Jr. Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiol Spectr, 2014, 2(4): MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013.
doi: 10.1128/microbiolspec.MGM2-0014-2013 |
[8] |
中华医学会结核病学分会临床检验专业委员会. 结核病病原学分子诊断专家共识. 中华结核和呼吸杂志, 2018, 41(9):688-695. doi: 10.3760/cma.j.issn.1001-0939.2018.09.008.
doi: 10.3760/cma.j.issn.1001-0939.2018.09.008 |
[9] |
Baker LV, Brown TJ, Maxwell O, et al. Molecular analysis of isoniazid-resistant Mycobacterium tuberculosis isolates from England and Wales reveals the phylogenetic significance of the ahpC-46A polymorphism. Antimicrob Agents Chemother, 2005, 49(4):1455-1464. doi: 10.1128/AAC.49.4.1455-1464.2005.
doi: 10.1128/AAC.49.4.1455-1464.2005 pmid: 15793126 |
[10] |
李亮, 唐神结, 杜建, 等. 建国70年我国结核病化学治疗的回顾与展望. 中华结核和呼吸杂志, 2019, 42(10):723-726. doi: 10.3760/cma.j.issn.1001-0939.2019.10.002.
doi: 10.3760/cma.j.issn.1001-0939.2019.10.002 |
[11] |
Zhang T, Jiang G, Wen S, et al. Para-aminosalicylic acid increases the susceptibility to isoniazid in clinical isolates of Mycobacterium tuberculosis. Infect Drug Resist, 2019, 12:825-829. doi: 10.2147/IDR.S200697.
doi: 10.2147/IDR.S200697 URL |
[12] | 马玙, 朱莉贞, 潘毓萱. 结核病. 北京:人民卫生出版社, 2006: 12. |
[13] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[14] |
马进宝, 任斐, 曾令城, 等. 2015—2019年西安市680例耐多药结核病患者耐药情况分析. 中国防痨杂志, 2020, 42(6):609-613. doi: 10.3969/j.issn.1000-6621.2020.06.013.
doi: 10.3969/j.issn.1000-6621.2020.06.013 |
[15] | 赵冰, 宋媛媛, 逄宇, 等. 中国耐多药结核分枝杆菌二线抗结核药物敏感性分析. 中国防痨杂志, 2013, 35(10):831-834. |
[16] |
宋艳华, 高孟秋, 李琦. 结核分枝杆菌对乙硫异烟胺/丙硫异烟胺耐药的机制及其增敏剂研究进展. 中国防痨杂志, 2020, 42(2):173-177. doi: 10.3969/j.issn.1000-6621.2020.02.017.
doi: 10.3969/j.issn.1000-6621.2020.02.017 |
[17] |
宋艳华, 王桂荣, 霍凤敏, 等. 耐多药和广泛耐药MTB的inhA基因基因突变与对丙硫异烟胺耐药的相关性分析. 中国防痨杂志, 2018, 40(8):821-824. doi: 10.3969/j.issn.1000-6621.2018.08.009.
doi: 10.3969/j.issn.1000-6621.2018.08.009 |
[18] |
Tan Y, Su B, Zheng H, et al. Molecular Characterization of Prothionamide-Resistant Mycobacterium tuberculosis Isolates in Southern China. Front Microbiol, 2017, 8:2358. doi: 10.3389/fmicb.2017.02358.
doi: 10.3389/fmicb.2017.02358 URL |
[19] |
Lee JH, Jo KW, Shim TS. Correlation between GenoType MTBDRplus Assay and Phenotypic Susceptibility Test for Prothionamide in Patients with Genotypic Isoniazid Resistance. Tuberc Respir Dis (Seoul), 2019, 82(2):143-150. doi: 10.4046/trd.2018.0027.
doi: 10.4046/trd.2018.0027 URL |
[20] |
Islam MM, Tan Y, Hameed HMA, et al. Detection of novel mutations associated with independent resistance and cross-resistance to isoniazid and prothionamide in Mycobacterium tuberculosis clinical isolates. Clin Microbiol Infect, 2019, 25(8):1041.e1-1041.e7. doi: 10.1016/j.cmi.2018.12.008.
doi: 10.1016/j.cmi.2018.12.008 |
[1] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[2] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[3] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[4] | Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373. |
[5] | Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163. |
[6] | Yan Guangxuan, Wang Xueyu, Wang Yujin, Lan Tinglong, Nie Wenjuan. Diagnostic value of using metagenomic second-generation sequencing on suspected osteoarticular tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 175-180. |
[7] | Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111. |
[8] | Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60. |
[9] | Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76. |
[10] | Chen Shuangshuang, Tian Lili, Wang Nenhan, Yang Xinyu, Zhao Yanfeng, Li Chuanyou, Dai Xiaowei. Analysis of in vitro antibacterial effects of 17 antibiotics against rapidly growing mycobacteria in the Beijing area [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1056-1062. |
[11] | Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068. |
[12] | Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang. Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082. |
[13] | Wang Biao, Liu Yuhong, Sun Yuxian, Zhang Lijie, Li Zhili, Shu Wei. Investigation and analysis of laboratory diagnostic capabilities in tuberculosis-designated hospitals in China [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1089-1097. |
[14] | Xue Yi, Liang Qian, Qi Haoran, Liang Ruixia, Huang Hairong. Reliability analysis of rifampicin-resistance detected by different diagnostics as a predictor for multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 892-896. |
[15] | Xu Chunhua, Zhu Shiyu, Hu Yi, Yi Kehua, Song Canlei, Wang Zichun, Wu Yong, Wang Qing, Yang Qianru, Shen Xin. Analysis of screening effect of recombinant Mycobacterium tuberculosis fusion protein in screening Mycobacterium tuberculosis infection in close contacts of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 897-902. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||